Nancy Tests SPARC-1036

Nancy tests Jira ticket SPARC-1036: Make anchor link work on initial page load

• Source: Shutterstock

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed dignissim quis mauris quis aliquam. In lacinia sagittis turpis, vitae eleifend dolor dignissim a. Maecenas semper nisl eu leo tempor lobortis. Nam sollicitudin sollicitudin eros, aliquet placerat ipsum malesuada vitae. Jump down to Oncology. Aliquam tempor bibendum elit, quis ultricies elit bibendum id. Ut non libero ullamcorper, aliquam erat in, posuere mauris. Interdum et malesuada fames ac ante ipsum primis in faucibus. Morbi velit risus, egestas sed euismod sed, eleifend et tortor. Aliquam elit felis, placerat nec venenatis id, scelerisque in nisi. Aenean iaculis ante vel tortor commodo imperdiet. Nunc tincidunt consectetur felis, ac porta ipsum pretium nec.

Vivamus hendrerit lectus et eleifend fermentum. Nunc gravida, nulla eget faucibus aliquam, lorem est vulputate turpis, nec sollicitudin massa magna...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By 

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Nancy Tests SPARC-1036

Nancy tests Jira ticket SPARC-1036: Make anchor link work on initial page load

Cagrisema Leads The Charge For 2025

 

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch

 

Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.    

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains